Prof. Dr. med. Michael Pinkawa

Prof. Dr. med. Michael Pinkawa

Kontakt aufnehmen

Prof. Dr. med. Michael Pinkawa

Chefarzt der Klinik für Strahlentherapie und Radioonkologie

Behandlungsschwerpunkte:

  • Prostatakarzinom
  • Bronchialkarzinom
  • Neuroonkologie

MEDICLIN Robert Janker Klinik

Ärztlicher Leiter

MVZ MEDICLIN Bonn

Lebenslauf

Studium

1991 - 1998

Studium der Humanmedizin an der RWTH Aachen und King’s College London / England

Ärztliche und wissenschaftliche Tätigkeit

1998 - 2004

Assistenzarzt in der Klinik für Strahlentherapie und der Klinik für Radiologische Diagnostik im Universitätsklinikum der RWTH Aachen

2004

Facharzt für Strahlentherapie

2004 - 2017

Oberarzt in der Klinik für Strahlentherapie im Universitätsklinikum der RWTH Aachen

2007

Habilitation („Optimierung der perkutanen Radiotherapie und der Brachytherapie bei der Behandlung des Prostatakarzinoms“)

2008 - 2017

leitender Oberarzt und stellvertretender Klinikdirektor in der Klinik für Strahlentherapie im Universitätsklinikum der RWTH Aachen

2012

Ernennung zum außerplanmäßigen Professor

2017

Chefarzt Klinik für Radioonkologie und Strahlentherapie an der MEDICLIN Robert Janker Klinik Bonn, Ärztlicher Leiter MVZ MEDICLIN Bonn mit voller Weiterbildung im Fach Strahlentherapie

2019

Ruf auf die W3-Professur für Strahlentherapie und Onkologie an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn (abgelehnt)

Sonstige Tätigkeiten

Fachexperte

Fachexperte für die Zertifizierung von Prostatakarzinomzentren und onkologischen Zentren der Deutschen Krebsgesellschaft

Mitglied im Ausschuss Zertifikatserteilung für Organzentren der Deutschen Krebsgesellschaft

Mitglied der Arbeitsgruppe Prostatakarzinom der Deutsche Gesellschaft für Radioonkologie

Experte der S3-Leitlinie Prostatakarzinom

SpaceOAR Advisory Board (Firma Boston Scientific)

Publikationen

Originalarbeiten

Aktuelle Publikationen von Prof. Pinkawa finden Sie in der National Library of Medicine.


1. Pinkawa M, Gagel B, Demirel C, Schmachtenberg A, Asadpour B, Eble MJ. Dose-volume histogram evaluation of prone and supine patient position in external beam radiotherapy for cervical and endometrial cancer. Radiother Oncol 2003;69:99-105.

2. Pinkawa M, Maurer U, Mulhern A, Gagel B, Block T, Borchers H, Grieger J, Henkel T, Eble MJ. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high- and low-activity 125I. Strahlenther Onkol 2003;179:417-422.

3. Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M, Eble MJ, Jakse G. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. BJU Int 2004;94:805-811.

4. Gagel B, Reinartz P, Dimartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher K, Coenen HH, Westhofen M, Bull U, Eble MJ. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-622.

5. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Oncol Biol Phys 2006;64:835-841.

6. Pinkawa M, Fischedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Dose-volume impact in high-dose-rate iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer - a phase II study. Radiother Oncol 2006;78:41-46.

7. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Holy R, Eble MJ. Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys 2006;64:856-861.

8. Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer - correlation with postimplant CT scan parameters. Strahlenther Onkol 2006;182:660-665.

9. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Association of neoadjuvant hormonal therapy with adverse health-related quality-of-life after permanent I-125 brachytherapy for localized prostate cancer. Urology 2006;68:104-109.

10. Pinkawa M, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol 2006;182:525-530.

11. Pinkawa M, Siluschek J, Gagel B, Demirel C, Asadpour B, Holy R, Eble MJ. Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer. Radiother Oncol 2006;81:284-290.

12. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth MD, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, and Eble MJ. [18F] fluoromisonidazol and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51.

13. Gagel B, Piroth MD, Pinkawa M, Reinartz P, Zimny M, Fischedick K, Stanzel S, Breuer C, Skobel S, Asadpour B, Schmachtenberg A, Buell U, and Eble M J. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer. Strahlenther Onkol 2006; 182:263-269.

14. Gagel B, Dimartino E, Schramm O, Pinkawa M, Piroth MD, Demirel C, Maneschi P, Stanzel S, Asadpour B, Westhofen M, Eble M.J. Contrast enhanced colour duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumour oxygenation? Strahlenther Onkol 2006;182:604-609.

15. Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ. Prostate-specific antigen kinetics following brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology 2007;69:129-133.

16. Pinkawa M, Siluschek J, Gagel B, Piroth MD., Demirel C, Asadpour B, Eble MJ. Postoperative radiotherapy for prostate cancer – evaluation of target motion and treatment techniques (intensity modulated versus conformal radiotherapy). Strahlenther Onkol 2007;183:23-29.

17. Pinkawa M, Asadpour B, Siluschek J, Gagel B, Piroth MD, Demirel C, Eble MJ. Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder. Radiother Oncol 2007;83:613-167.

18. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Evaluation of source displacement and dose-volume changes after permanent prostate brachytherapy with stranded seeds. Radiother Oncol 2007;84:190-196.

19. Gagel B, Demirel C, Kientopf A, Pinkawa M, Piroth MD, Stanzel S, Breuer C, Asadpour B, Jansen T, Holy R, Wildberger J, Eble MJ. Active breathing control (ABC): determination and reduction of breathing induced organ motion in the chest. Int J Radiat Oncol Biol Phys 2007;67:742-749.

20. Gagel B, Piroth MD, Pinkawa M, Reinartz P, Krohn T, Kaiser HJ, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble MJ. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radio-/chemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. BMC Cancer 2007;7:112.

21. Gagel B, Piroth MD, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E, Eble MJ. pO2 polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoroimisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113.

22. Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol 2007;183:695-702.

23. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen, Eble MJ. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83-89.

24. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth M, Holy R, Krenkel B, Eble MJ. Health-related quality of life after adjuvant and salvage radiotherapy for prostate cancer – a prospective analysis. Radiother Oncol 2008; 88:135-139.

25. Pinkawa M, Gagel B, Asadpour B, Piroth MD, Klotz J, Borchers H, Jakse G, Eble MJ. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level. Strahlenther Onkol 2008;184:520-525.

26. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, Nussen S, Eble MJ. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol 2008;184:679-685.

27. Kirschner-Hermanns R, Brehmer B, Borchers H, Kahle C Eble MJ, Reineke T, Jakse G, Pinkawa M. Do patients with urodynamically proven infravesical obstruction and detrusor overactivity have a higher risk for long term bothersome symptoms after brachytherapy in comparison to patients treated with radical prostatectomy for localized prostate cancer? Curr Urol 2008;2:135-141.

28. Piroth MD, Pinkawa M, Gagel B, Stanzel S, Asadpour B, Eble MJ. Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy – a retrospective analysis. BMC Cancer 2008;8:114.

29. Volz-Sidiropoulou E, Pinkawa M, Fischedick K, Jakse G, Gauggel S, Eble MJ. Factor analysis of the expanded prostate cancer index composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. Curr Urol 2008;2:122-129.

30. Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, Klotz J, Eble MJ. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009;55:227-236.

31. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M, Borchers H, Jakse G, Eble MJ. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer – a matched-pair comparison. Radiother Oncol 2009;91:225-231.

32. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Klotz J, Fischedick K, Borchers H, Jakse G, Eble MJ. Rectal dosimetry following prostate brachytherapy with stranded seeds – comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs day 30) with special focus on sourced placed close to the rectal wall. Radiother Oncol 2009;91:207-212.

33. Pinkawa M, Piroth MD, Asadpour B, Gagel B, Fischedick K, Siluschek J, Kehl M, Krenkel B, Eble MJ. Neoadjuvant hormonal therapy and external beam radiotherapy versus external beam radiotherapy alone for prostate cancer – a quality of life analysis. Strahlenther Onkol 2009;185:101-108.

34. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, Hawickhorst R, Schäfer W, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 2009;93:213-219.

35. Pinkawa M, Piroth MD, Fischedick K, Holy R, Klotz J, Nussen S, Krenkel B, Eble MJ. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external beam radiotherapy for prostate cancer. Strahlenther Onkol 2009; 185:724-730.

36. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Asadpour B, Klotz J, Borchers H, Jakse G, Eble MJ. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009;9:296.

37. Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, Eble MJ. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer - predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiation Oncology 2009;4:36.

38. Piroth MD, Piroth DM, Pinkawa M, Woodruff SG, Holy R, Eble MJ. Immediate reconstruction with an expander/implant following ablation mammae because of breast cancer: side effects and cosmetic results after adjuvant chest wall radiotherapy. Strahlenther Onkol 2009;185:669-674.

39. Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ, Eble MJ. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme. Radiat Oncol 2009;4:57.

40. Pinkawa M, Piroth MD, Holy B, Klotz J, Nussen S, Borchers H, Heidenreich A, Eble MJ. Rectal morbidity following permanent interstitial brachytherapy for prostate cancer – impact of day 1 vs. day 30 computed tomography post-implant dosimetry. Brachytherapy 2010;9:1-7.

41. Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Dalma Székely-Orbán, Eble MJ. Consequential late effects after radiotherapy for prostate cancer – a prospective longitudinal quality of life study. Radiat Oncol 2010;5:27.

42. Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Borchers H, Heidenreich A, Eble MJ. Prostate-specific antigen kinetics following external beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol 2010;96:25-29.

43. Pinkawa M, Holy R, Piroth MD, Klotz J, Schaar S, Krohn T, Mottaghy FM, Weibrecht M, Eble MJ. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2010;186:600-606.

44. Piroth MD, Heindrichs U, Pinkawa M, Piroth DM, Schmachtenberg A, Holy R, Perez-Bouza A, Maass N, Eble MJ. Intraoperative Radiotherapie (IORT) des Mammakarzinoms mit Elektronen – eigene Erfahrungen, aktuelle Aspekte und Literaturübersicht. Geburtshilfe Frauenheilkd 2010;70:219-225.

45. Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Székely-Orbán D, Eble MJ. Quality of life after whole pelvic versus prostate only external beam radiotherapy for prostate cancer – a matched-pair comparison. Int J Radiat Oncol Biol Phys 2011;81:23-28.

46. Pinkawa M, Holy R, Piroth MD, Klotz J, Pfister D, Heidenreich A, Eble MJ. Interpreting the clinical significance of quality of life score changes after radiotherapy for localized prostate cancer. Curr Urol 2011;5:137-144.

47. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011;187:479-484.

48. Pinkawa M, Escobar Corral N, Caffaro M, Piroth MD, Holy R, Djukic V, Otto G, Schoth F, Eble MJ. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011;100:436-441.

49. Holy R, Pitoth MD, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-251.

50. Peinemann F, Grouven U, Bartel C, Hemkens LG, Borchers H, Pinkawa M, Heidenreich A, Sauerland S. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 2011;7:CD008871.

51. Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, Heidenreich A, Lange S. Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 2011;60:881-893.

52. Piroth MD, Pinkawa M, Holy R, Kaiser HJ, Klotz J, Schaar S, Stoffels G, Coenen HH, Langen KJ, Eble MJ. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-184.

53. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Gallsiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ. Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011;99:218-224.

54. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Escobar Corral N, Caffaro M, Winz OH, Krohn T, Mottaghy FM, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol 2012;7:14.

55. Pinkawa M, Holy R, Piroth MD, Klotz J, Pfister D, Heidenreich A, Eble MJ. Urinary morbidity after permanent prostate brachytherapy – impact of dose to the urethra vs. sources placed in close vicinity to the urethra. Radiother Oncol 2012;103:247-251.

56. Brzozowska K, Pinkawa M, Eble MJ, Müller WU, Wojcik A, Kriehuber R, Schmitz S. In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. Int J Radiat Biol 2012;88:405-113.

57. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, Galldiks N, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas: results of a prospective phase II study. Strahlenther Onkol 2012;188:334-339.

58. Galldiks N, Langen KJ, Holy, R, Pinkawa M, Stoffels G, Kaiser H, Filss C, Fink G, Coenen C, Eble MJ, Piroth MD. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-1057.

59. Hatiboglu G, Pinkawa M, Vallée J, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 2012;110:E647-652.

60. Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Djukic V, Klotz J, Eble MJ. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer – matched-pair comparisons. Strahlenther Onkol 2012;188:917-925.

61. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Pfister D, Heidenreich A, Eble MJ. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol 2012;7:209.

62. Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, DeWeese TL, Ford EC. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 2013;87:81-87.

63. Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Klotz J, Eble MJ. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiother Oncol 2013;106:220-224.

64. Yang Y, Ford EC, Wu B, Pinkawa M, van Triest B, Campbell P, Song DY, NcNutt TR. An overlap-volume-histogram based method for rectal dose prediction and automated treatment planning in external beam prostate radiotherapy following hydrogel injection. Med Phys 2013;40:011709

65. Pinkawa M, Klotz J, Djukic V, Schubert C, Escobar-Corral N, Caffaro M, Piroth MD, Holy R, Eble MJ. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancerUrology 2013;82:963-968.

66. Schmitz S, Brzozowska K, Pinkawa M, Eble M, Kriehuber R. Chromosomal radiosensitivity analyzed by FISH in lymphocytes of prostate cancer patients and healthy donors. Radiat Res 2013;180:465-73.

67. Piroth MD, Fischedick K, Wein B, Heindrichs U, Piroth DM, Holy R, Pinkawa M, Eble MJ. Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison. Breast Cancer 2014;21:409-414.

68. Pinkawa M, Djukic V, Klotz J, Piroth MD, Holy R, Eble MJ. Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. Future Oncol 2014;10:832-43.

69. Pinkawa M, Klotz J, Djukic V, Petz D, Holy R, Eble MJ. Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life. Int J Urol 2014;21:899-903.

70. Uhl M, Herfarth K, Eble MJ, Pinkawa M, Van Triest B, Kalisvaart R, Weber DC, Miralbell R, Song DY, DeWeese TL. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 months toxicity and proctoscopy results of a multicenter phase II trial. Radiat Oncol 2014;9:96.

71. Peinemann F, Labeit AM, Thielscher C, Pinkawa M. Failure to address potential bias in nonrandomized controlled clinical trials may cause lack of evidence on patient-reported outcomes – a method study. BMJ Open 2014;4:e004720.

72. Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble MJ. Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlenther Onkol 2015;191:771-777.

73. Pinkawa M, Brzozowska K, Kriehuber R, Eble MJ, Schmitz S. Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients. Future Oncol 2016;12:617-624.

74. Piroth MD, Petz D, Pinkawa M, Holy R, Eble MJ. Usefullness of a thermoplastic breast bra for breast cancer radiotherapy to reduce heart and lung dose – a prospective study . Strahlenther Onkol 2016;192:609-616.

75. Müller A, Mischinger J, Klotz T, Gagel B, Habl G, Hatiboglu G, Pinkawa M. Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in >250 patients. Radiol Oncol 2016;50:329-336.

76. Vanneste BGL, Hoffmann AL, van Lin EN, Van de Voorde L, Pinkawa M, Lambin P. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy. Radiother Oncol 2016;121:118-123.

77. Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, Mottaghy FM, Shah NJ, Langen KJ, Eble MJ. Relapse patterns after radiochemotherapy of glioblastoma with FET-PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 2016;11:87.

78. Pinkawa M, Berneking V, König L, Frank D, Bretgeld M, Eble MJ. Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. Strahlenther Onkol 2017;193:22-28.

79. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of life after radiotherapy for prostate cancer with a hydrogel spacer – five year results. Int J Radiat Oncol Biol Phys 2017;99:374-377.

80. Freiberger C, Berneking V, Vögeli T, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer – focus on overall survival. Radiat Oncol 2017;12:98

81. van Wijk Y, Vanneste BGL, Walsh S, van der Meer S, Ramaekers B, van Elmpt W, Pinkawa M, Lambin P. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: comparision of dose, toxicity and cost-effectiveness. Radiother Oncol 2017;125:107-112.

82. Pinkawa M, Schubert C, Escobar-Corral N, Berneking V, Eble MJ. Optimization of prostate cancer radiotherapy using a spacer gel, volumetric modulated arc therapy and a single biological organ at risk objective. Int J Radiat Res 2018;16:169-176.

83. Freiberger C, Berneking V, Vogeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer. Brachytherapy 2018;17:517-523.

84. Schlenter M, Berneking V, Krenkel B, Mottaghy FM, Vogeli TA, Eble MJ, Pinkawa M. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life. Strahlenther Onkol 2018;194:638-645.

85. van Wijk Y, Vanneste BGL, Jochems A, Walsh S, Oberije CJ, Pinkawa M, Ramaekers BLT, Vega A, Lambin P. Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. Acta Oncol 2018; 57:1499-1505.

86. Leufgens F, Berneking V, Vogeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer. Acta Oncol 2019:1-7.

87. Leufgens F, Berneking V, Vogeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2019;105:382-388.

88. Vanneste BGL, Buettner F, Pinkawa M, Lambin P, Hoffmann AL. Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clin Transl Radiat Oncol 2019;14:17-24.

89. Leufgens F, Berneking V, Vogeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer. Acta Oncol 2020;59:157-163.

90. Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e208221.

91. Seymour ZA, Hamstra DA, Daignault-Newton S, Bosch W, Michalski J, Gay HA, Pinkawa M. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. BJU Int 2020 (in press).

Übersichtsartikel/Empfehlungen

1. Pinkawa M, Eble MJ. Prostatakarzinom. Stadienorientierte Primärtherapie - Strahlentherapie. Onkologie heute 2009;2:29-34.

2. Pinkawa M, Heidenreich A. Prostatakarzinom. Therapie des Rezidivs nach Primärtherapie. Onkologie heute 2009;2:36-44.

3. Pinkawa M, Gontero P. The motion: radiotherapy for prostate cancer preserves sexual function to a greater extent than nerve sparing radical prostatectomy. Eur Urol 2009;56:212-214.

4. Pinkawa M. External beam radiotherapy for prostate cancer. Panminerva Med 2010;53:195-207.

5. Pinkawa M, Eble MJ, Mottaghy FM. PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev Anticancer Ther 2011;7:1035-41.

6. Heidenreich A, Wilop S, Pinkawa M, Porres D, Pfister D. Metastasenresektion urologischer Tumoren. Dtsch Arztebl Int 2012;109:631-617.

7. Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, Eble MJ. Current standards and future directions for prostate cancer radiation therapy. Expert Rev Anticancer Ther 2013;13:75-88.

8. Pinkawa M. Spacer application for prostate cancer radiation therapy. Future Oncol 2014;10:851-64.

9. Pinkawa M. Recent advances in definitive radiotherapy for prostate cancer. EMJ Oncol 2015;3:41-48.

10. Pinkawa M. Aktuelle Konzepte und Entwicklungen in der Strahlentherapie. TumorDiagn und Ther 2015;36:2-5.

11. Pinkawa M. Zoledronic acid in first-line treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2017;97:6-8.

12. Padmanabham R, Pinkawa M, Song D. Hydrogel spacers in prostate radiotherapy: a promising approach to lower rectal toxicity. Future Oncol 2017;29:2697-2708.

13. Ghadjar P, Fiorino C, Munck Af Rosenschold P, Pinkawa M, Zilli T, van der Heide UA: ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol 2019:141:5-13.

14. Beck M, Bohmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Wiegel T. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol 2020;196:109-116.

15. Kovács A, Pinkawa. Interventional therapy in malignant conditions of the prostate. Radiologe 2019;59:28-39.

16. Ghadjar P, Aebersold DM, Albrecht C, Bohmer D, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 2020; 196:589-597.

Fallberichte

1. Borchers H, Pinkawa M, Donner A, Wolter TP, Pallua N, Eble MJ, Jakse G. Rectourethral fistula following LDR brachytherapy. Urologia Internationalis 2009;82:365-366.

2. Peinemann, Pinkawa M. Treatment of locally advanced prostate cancer: a case report and narrative review. Case Rep Urol 2012;2012.

3. Pinkawa M, Bornemann C, Escobar-Corral N, Piroth MD, Holy R, Eble MJ. Treatment planning after hydrogel injection during radiotherapy of prostate cancer Strahlenther Onkol 2013;189:796-800.

4. Schmitz S, Pinkawa M, Eble MJ, Kriehuber R. Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient-a case report. Mutat Res 2013;756:158-164.

5. Pinkawa M, Schubert C, Escobar-Corral N, Holy R, Eble MJ. Application of a hydrogel spacer for postoperative salvage radiotherapy for prostate cancer. Strahlenther Onkol 2015;191:375-379.

6. Pinkawa M. Salvage treatment options for recurrent seminoma? Int J Radiat Oncol Biol Phys 2017;99:510.

7. Pinkawa M. Spinal cord re-irradiation – balancing benefit against risks. Int J Radiat Oncol Biol Phys 2020 (in press).

Editorials

1. Pinkawa M. Editorial comment on: Prognostic factors for late urinary toxicity grade 2-3 after conformal radiation therapy on patients with prostate cancer. Int Braz J Urol 2007;33:660.

2. Pinkawa M. Editorial comment on: Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing brachytherapy? J Urol 2010;183:641.

3. Pinkawa M. Current role of spacers for prostate cancer radiotherapy. World J Clin Oncol 2015;10:189-193.

4. Pinkawa M. Benefit from local treatment of the primary tumor in patients with metastatic prostate cancer at diagnosis. J Xiangya Med 2017;2:66.

5. Pinkawa M. Therapie der primären Finger- und Daumengelenkarthrose: Strahlentherapie. Dtsch Arztebl Int 2018, 115(35-36):596.

6. Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, Spratt DE. STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer? Int J Radiat Oncol Biol Phys 2019;104:33-35.

7. Mitin T, Henry A, Choudhury A, Chen RC, Pinkawa M, Spratt DE. SBRT for Localized Prostate Cancer: Is it Ready for Take-Off? Int J Radiat Oncol Biol Phys 2019, 105:618-620.

Buchbeiträge

Titel: Innovative Radiotherapy Techniques for Prostate Cancer

UNI-MED Verlag AG Bremen; Reihe: UNI-MED SCIENCE; 2012

ISBN 978-3-8374-1385-4

Eigene Rolle: Herausgeber und Autor mehrerer Beiträge:

1. Radiotherapy as a primary definitive treatment for localized prostate cancer. S. 12-19.

2. Image-guided radiotherapy – Ultrasound-based image-guided radiotherapy. S. 22-24.

3. Image-guided radiotherapy – Electromagnetic real-time tracking. S. 25-27.

4. Simultaneous integrated boost – Choline positron emission tomography. S. 31-35.

5. Particle beam radiotherapy. S. 36-39.

6. Spacer between prostate and anterior rectal wall – Clinical experience. S. 45-49.

Titel: Komplikationen in der urologischen Diagnostik und Therapie
Springer-Verlag Heidelberg 2020 (in Druck)
Herausgeber: Kranz, Anheuser, Steffens
Eigene Rolle: Autor des Beitrags:
Organspezifische Komplikationen der Strahlentherapie - Prostata

Fachgesellschaften

Mitgliedschaften

Deutsche Gesellschaft für Radioonkologie (DEGRO)

European Society for Radiotherapy and Oncology (ESTRO)

American Society for Therapeutic Radiology and Oncology (ASTRO)

Berufsverband der Deutschen Strahlentherapeuten (BVDST)

Mitglied Editorial Board

International Journal of Radiation Oncology Biology Physics (2015-2019)

Mit Klick / Tap können Sie die interaktiven Kartenfunktionen nutzen. Dafür gelten die Datenschutzerklärungen von Google